Find all the latest information in acute myeloid leukemia, arranged by types, translocations, and mutations. Listed below are recently updated categories.
Combination of myeloablative conditioning with regulatory and conventional T-cell immunotherapy for AML
The most effective treatment for high-risk acute myeloid leukemia (AML) is allogeneic...
How has the COVID-19 pandemic impacted patients with AML?
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the AML Hub spoke with Talati Chetasi, Moffitt Cancer Center,...
Venetoclax with HMA: A bridge to transplant in high-risk acute myeloid leukemia
High-risk acute myeloid leukemia (AML) is characterized by a high frequency of cytogenetic adverse-risk features which...
Prognostic impact of FLT3-ITD and CEBPA mutations in cytogenetically normal AML
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) have varied clinical outcomes, and advances in...
EMA CHMP grants positive opinion for venetoclax in combination with hypomethylating agents for the treatment of patients with newly diagnosed AML
On April 23, 2021, the European Medicines Agency (EMA)...
CC-486 receives positive CHMP opinion for the treatment of adult patients with AML in first remission
Very recently, it was announced that the Committee for Medicinal Products for Human Use (CHMP)...
SNDX-5613 shows encouraging overall response rate in relapsed/refractory acute leukemias
SNDX-5613, a potent, highly selective, oral inhibitor of the menin-mixed lineage leukemia (MLL) binding...
FDA approves extended indication of daunorubicin plus cytarabine to include pediatric patients with AML
On March 30, 2021, the U.S. Food and Drug Administration (FDA) approved an extended indication...
Core binding factor